Spero Therapeutics enters immunology with an antibody licensed from Innovent Biologics. The lead indication is a uncommon autoimmune situation the place Spero goals to supply benefits over the Amgen drug that’s at present the one accredited remedy.
The publish After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset appeared first on MedCity Information.
